Stereotactic Radiotherapy
What we treat
Select treatment
by cancer type
Targeting cancer
Discover more about what cancers we treat
Select treatment
by cancer type
Brain Treatment
At Pinpoint Radiotherapy, we specialise in providing targeted, personalised treatment for patients facing disease of the brain.
Brain metastases occur when cancer cells spread to the brain from a primary tumour, commonly originating from cancers such as lung, breast, or melanoma. These metastases can cause neurological issues, including cognitive decline, seizures, and other deficits that significantly reduce a patient's quality of life. Traditional treatments like whole-brain radiotherapy (WBRT), surgery, and chemotherapy often come with severe side effects, particularly cognitive deterioration.
Stereotactic Radiosurgery (SRS) has become a preferred treatment option for brain metastases. This non-invasive approach delivers focused, high-dose radiation to the metastases, or surgical cavity if resected, sparing healthy brain tissue and reducing cognitive side effects often seen with WBRT. SRS typically requires fewer treatment sessions, often just one, and offers excellent local control for patients with limited brain metastases.
No risk. Find out if you are, or are
not, suitable for our service
Spine Treatment
At Pinpoint Radiotherapy, we specialise in providing targeted, personalised treatment for patients facing disease of the spine.
Spinal metastases, commonly arising from cancers such as breast, lung, or prostate, can cause severe pain, spinal cord compression, and neurological issues, significantly affecting mobility and quality of life. Traditional treatments like surgery, chemotherapy, and radiotherapy are often effective but can involve long treatment times and may damage surrounding tissues.
Stereotactic Ablative Radiotherapy (SABR) has emerged as a precise, minimally invasive option for treating spinal metastases. SABR delivers high-dose radiation directly to spinal lesions with pinpoint accuracy, sparing the spinal cord and healthy vertebrae. Its precision reduces the risk of serious complications like paralysis while offering significant pain relief and tumour control, often in just a few treatment sessions.
No risk. Find out if you are, or are
not, suitable for our service
Lung Treatment
At Pinpoint Radiotherapy, we specialise in providing targeted, personalised treatment for patients facing early-stage lung cancer or metastatic disease of the lung.
Early-stage lung cancer presents a critical opportunity for effective treatment, but traditional surgical options can be risky for patients with underlying health conditions. Stereotactic Ablative Radiotherapy (SABR) stands out as a superior alternative to conventional radiotherapy, offering higher precision and better outcomes. By delivering highly focused, high-dose radiation directly to the tumour, SABR achieves greater tumour control with fewer treatment sessions, significantly improving both effectiveness and convenience for patients.
With local control rates exceeding 90%, SABR provides a faster, non-invasive option for those who are not candidates for surgery, making it a more patient-friendly and powerful treatment for early-stage lung cancer.
No risk. Find out if you are, or are
not, suitable for our service
Liver Treatment
At Pinpoint Radiotherapy, we specialise in providing targeted, personalised treatment for patients facing primary liver cancer or metastatic disease of the liver.
Primary liver cancers like hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma, as well as metastatic liver disease, present challenges due to the liver’s critical functions and sensitivity. Standard treatment options such as surgery, are often not feasible for patients with underlying conditions like cirrhosis, necessitating non-invasive alternatives.
Stereotactic Ablative Radiotherapy (SABR) provides a precise, non-invasive option by using advanced imaging and motion management techniques to target tumours while sparing healthy tissue, which can reduce complications like liver impairment/failure. SABR also requires fewer sessions than conventional therapies. Studies show local control rates exceeding 90%, making SABR an effective choice for patients who cannot undergo surgery.
No risk. Find out if you are, or are
not, suitable for our service
Kidney Cancer Treatment
At Pinpoint Radiotherapy, we specialise in providing targeted, personalised treatment for patients facing primary kidney cancer.
Primary kidney cancer, particularly renal cell carcinoma (RCC), can be challenging to treat, especially for patients who are medically or technically unsuited for surgery due to factors like age, health conditions, or tumour location. While nephrectomy is a standard treatment, many patients require a non-invasive alternative.
Stereotactic Ablative Radiotherapy (SABR) offers a targeted, non-invasive option by delivering precise, high-dose radiation to the tumour while preserving healthy kidney function. It involves a few sessions and has mild side effects. Studies show SABR achieves a local failure rate of 5.5% and over 90% cancer-specific survival, making it an effective treatment for early-stage RCC in patients unable to undergo surgery.
No risk. Find out if you are, or are
not, suitable for our service
Prostate Cancer Treatment
At Pinpoint Radiotherapy, we specialise in providing targeted, personalised treatment for patients facing prostate cancer.
Prostate cancer is common among men, and while surgery is often a primary treatment option, not all patients are suitable candidates due to factors such as age, comorbidities, or tumour location. In these cases, effective non-invasive treatment options like radiotherapy are crucial for managing the disease while maintaining quality of life.
Stereotactic Ablative Radiotherapy (SABR) offers a highly precise, non-invasive approach to treating localised prostate cancer. Compared to traditional radiotherapy, SABR delivers high-dose radiation in fewer sessions, providing similar tumour control in a more convenient schedule. This shorter treatment time, combined with its accuracy in sparing nearby organs, makes SABR an attractive option offering excellent outcomes with less burden on patients.
In addition, patients with a rising PSA after prostatectomy or prostate radiotherapy may harbour disease that is amenable to further treatment. In Australia, patients with prostate cancer relapse are eligible for two Medicare funded PSMA-PET scans. We can advise on timing of, and assist with arranging advanced PSMA-PET imaging to help identify the precise location of relapsed disease that may be targeted and eliminated with SABR treatment as a second attempt at cure, or to avoid or delay the need for further therapy, (such as hormone therapy/ADT).
No risk. Find out if you are, or are
not, suitable for our service
Oligometastatic Disease
At Pinpoint Radiotherapy, we specialise in providing targeted, personalised treatment for patients facing Oligometastatic disease.
Oligometastatic disease, defined as a limited number of metastatic lesions, presents a unique opportunity for localised treatments that can improve patient outcomes. Stereotactic Ablative Radiotherapy (SABR) offers a precise, non-invasive way to target metastatic lesions in various organs while sparing healthy tissue. This approach reduces side effects and helps manage the disease more effectively.
Emerging evidence supports SABR’s ability to delay systemic therapies and extend survival in patients with oligometastatic disease, making it a transformative option that offers a powerful method for controlling cancer progression while preserving quality of life.
No risk. Find out if you are, or are
not, suitable for our service
Cancer Treatment
What is Stereotactic
Radiotherapy
Stereotactic Ablative Radiotherapy (SABR) is an advanced, non-invasive cancer treatment that delivers highly targeted, high-dose radiation to tumours while sparing surrounding healthy tissue. SABR utilises advanced 3D imaging and cutting-edge treatment delivery systems to precisely identify and treat tumours with pinpoint accuracy.
It is ideal for treating small, well-defined tumours and is delivered in shorter courses compared to traditional radiotherapy. It offers an effective option for patients who are not candidates for, or wish to avoid, surgery. This approach represents a leap forward in cancer care, providing patients with a fast, highly effective and safe treatment experience.
Benefits of Stereotactic Radiotherapy
Non-invasive treatment
Low risk with no recovery time
Short treatment course
1 to 2 Weeks
Minimise disruption in your life
Treat with
precision
Effective Treatment
Minimal side effects
Effective & precise
No wait-list
Immediate consultation
Learn more about our team of Radiation Oncologists
Dr Patrick Bowden
MBBS, FRANZCR
Learn more about
Dr Bowden
Dr Paul Conway
BHlthSci, GradDipHlthSci, MBBS (Hons), FRANZCR
Learn more about
Dr Conway
- Caring team of experts
- Melbourne & Canberra
- Ready to listen & help
